Vincent Verdier, Christophe O Soulage, Laetitia Koppe
doi : 10.1093/ndt/gfab269
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 1–4
Kate I Stevens, Edoardo Melilli
doi : 10.1093/ndt/gfab273
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 5–7
Kitty J Jager, Anders Åsberg, Frederic Collart, Cécile Couchoud, Marie Evans, Patrik Finne, Ileana Peride, Ivan Rychlik, Ziad A Massy
doi : 10.1093/ndt/gfab252
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 8–13
Natasha N Dave, Matthew A Sparks, Samira S Farouk
doi : 10.1093/ndt/gfaa067
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 14–20
The use of social media has increased over the last several decades, with ?72% of the US adult population indicating the use of social networking platforms. Expansion of social media use beyond personal reasons now includes professional uses. This growth is especially true in medicine—and specifically nephrology. An enhanced online presence has the potential to make positive contributions to professional development, education and collaborations, potentially opening doors to academic opportunities. With a growing number of online platforms, resources and conversations, it is natural for one to feel overwhelmed and ultimately avoid social media. We discuss the benefits of social media engagement for nephrologists and provide a practical guide on how they can harness social media professionally and effectively. With an understanding of the basics, existing resources and avoidance of potential pitfalls, physicians can learn to use social media and join the global nephrology community.
Carmine Zoccali, Raymond Vanholder, Carsten A Wagner, Hans-Joachim Anders, Peter J Blankestijn, Annette Bruchfeld, Giovambattista Capasso, Mario Cozzolino, Friedo W Dekker, Danilo Fliser, Denis Fouque, Ron T Gansevoort, Dimitrios Goumenos, Kitty J Jager, Ziad A Massy, Tom A J Oostrom, Ivan Rychl?k, Maria Jose Soler, Kate Stevens, Goce Spasovski, Christoph Wanner
doi : 10.1093/ndt/gfaa163
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 21–28
Medical societies have a social responsibility to disseminate knowledge and inform health authorities on threats to public health posed by various diseases. Advocacy for health protection programmes and for medical research funding is now embedded into the missions of most scientific societies. To promote kidney research funding in Europe, the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA), rather than acting as an individual society advocating for the fight against kidney disease, has actively helped to create an alliance of national associations centred on kidney diseases, the European Kidney Health Alliance (EKHA), and joined the Biomedical Alliance (BMA). The ERA-EDTA is fully committed to supporting its working groups (WGs) and consortia of its members to allow them to produce valuable kidney research. The framing and formalization of projects, and the regulatory issues related to submission to the European Commission, are complex. To help WGs to gain expert advice from agencies with specific know-how, the ERA-EDTA has adopted a competitive approach. The best research projects proposed by WGs and consortia of other European investigators will receive seed funding to cover the costs of consultancy by expert agencies. Via its broader platforms, the EKHA and the BMA, the ERA-EDTA will strive towards broader recognition of kidney disease and related clusters of non-communicable diseases, by European and national agencies, as major threats to the qualities of life of their populations and their economies.
Sara S Jdiaa, Stephen B Walsh, Detlef Bockenhauer, Sara W Fakhredine, Sahar H Koubar
doi : 10.1093/ndt/gfaa100
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 29–30
Michel Burnier
doi : 10.1093/ndt/gfaa108
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 31–32
Guizhen Yu, Yong Zhang, Bo Meng, Xinfang Xie, Zi Wang, Wantao Ying, Jicheng Lv, Hong Zhang
doi : 10.1093/ndt/gfab204
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 33–41
Immunoglobulin A1 (IgA1) O-glycosylation plays an important role in the pathogenesis of IgA nephropathy (IgAN). However, variations in IgA1 O-glycoforms have not been explored. We aimed to investigate the IgA1 O-glycoforms in the hinge region (HR) of polymeric IgA1 (pIgA1) and then evaluate the association between IgA1 O-glycoforms and crescent formation in IgAN.
Michael Rudnicki, Justyna Siwy, Ralph Wendt, Mark Lipphardt, Michael J Koziolek, Dita Maixnerova, Björn Peters, Julia Kerschbaum, Johannes Leierer, Michaela Neprasova, Miroslaw Banasik, Ana Belen Sanz, Maria Vanessa Perez-Gomez, Alberto Ortiz, Bernd Stegmayr, Vladimir Tesar, Harald Mischak, Joachim Beige, Heather N Reich, PERSTIGAN working group
doi : 10.1093/ndt/gfaa307
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 42–52
Risk of kidney function decline in immunoglobulin A (IgA) nephropathy (IgAN) is significant and may not be predicted by available clinical and histological tools. To serve this unmet need, we aimed at developing a urinary biomarker-based algorithm that predicts rapid disease progression in IgAN, thus enabling a personalized risk stratification.
Hiroaki Yonishi, Tomoko Namba-Hamano, Takayuki Hamano, Masaki Hotta, Jun Nakamura, Shinsuke Sakai, Satoshi Minami, Takeshi Yamamoto, Atsushi Takahashi, Wataru Kobayashi, Ikuhiro Maeda, Yoh Hidaka, Yoshitsugu Takabatake, Norio Sakai, Yoshitaka Isaka
doi : 10.1093/ndt/gfaa298
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 53–62
The inability of enzyme replacement therapy (ERT) to prevent progression of Fabry nephropathy (FN) in the presence of >1?g/day proteinuria underscores the necessity of identifying effective biomarkers for early diagnosis of FN preceding proteinuria. Here we attempted to identify biomarkers for early detection of FN.
Karl Emil Nelveg-Kristensen, Wladimir Szpirt, Nicholas Carlson, Mark McClure, David Jayne, Hans Dieperink, Jon Waarst Gregersen, Elizabeth Krarup, Per Ivarsen, Christian Torp-Pedersen, Martin Egfjord
doi : 10.1093/ndt/gfaa303
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 63–71
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) carries a high risk of morbidity and mortality, with outcomes modified by treatment and an incidence that may be increasing. We examined temporal changes in incidence and mortality during 2000–15 using nationwide healthcare registries.
Michael T Eadon, Sam Lampe, Mirza M Baig, Kimberly S Collins, Ricardo Melo Ferreira, Henry Mang, Ying-Hua Cheng, Daria Barwinska, Tarek M El-Achkar, Tae-Hwi Schwantes-An, Seth Winfree, Constance J Temm, Michael J Ferkowicz, Kenneth W Dunn, Katherine J Kelly, Timothy A Sutton, Sharon M Moe, Ranjani N Moorthi, Carrie L Phillips, Pierre C Dagher, for the Kidney Precision Medicine Project
doi : 10.1093/ndt/gfaa331
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 72–84
Idiopathic nodular mesangial sclerosis, also called idiopathic nodular glomerulosclerosis (ING), is a rare clinical entity with an unclear pathogenesis. The hallmark of this disease is the presence of nodular mesangial sclerosis on histology without clinical evidence of diabetes mellitus or other predisposing diagnoses. To achieve insights into its pathogenesis, we queried the clinical, histopathologic and transcriptomic features of ING and nodular diabetic nephropathy (DN).
Rachel G Armani, Aluizio B Carvalho, Christiane I Ramos, Valeria Hong, Luiz A Bortolotto, Jose Luiz Cassiolato, Natacha F Oliveira, Zuzana Cieslarova, Claudimir L do Lago, Aline Klassen, Lilian Cuppari, Dominic S Raj, Maria Eugênia F Canziani
doi : 10.1093/ndt/gfaa335
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 85–91
Microbiota-derived uremic toxins have been associated with inflammation that could corroborate with endothelial dysfunction (ED) and increase cardiovascular risk in patients with chronic kidney disease (CKD). This trial aimed to evaluate the effect of the prebiotic fructooligosaccharide (FOS) on endothelial function and arterial stiffness in nondialysis CKD patients.
Bjørn Steinar Lillås, Camilla Tøndel, Jörg Aßmus, Bjørn Egil Vikse
doi : 10.1093/ndt/gfaa306
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 92–99
Low birthweight (LBW) has been shown to increase the risk of severe kidney disease. Studies have also shown associations between LBW and lower estimated glomerular filtration rate (GFR) in young adults. In this study we investigated whether LBW associates with measured GFR (mGFR) in middle-aged mainly healthy adults.
Niels S Heinrich, Simone Theilade, Signe A Winther, Nete Tofte, Tarunveer S Ahluwalia, Jørgen L Jeppesen, Frederik Persson, Tine W Hansen, Jens P Goetze, Peter Rossing
doi : 10.1093/ndt/gfaa308
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 100–107
Plasma copeptin is a surrogate of arginine vasopressin (AVP) secretion and is associated with a risk of renal and cardiovascular disease. We investigated associations between copeptin and renal events, cardiovascular events and mortality in type 1 diabetes (T1D).
Rupert W Major, David Shepherd, James F Medcalf, Gang Xu, Laura J Gray, Nigel J Brunskill
doi : 10.1093/ndt/gfaa291
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 108–114
South Asian (SA) individuals are more likely to develop end-stage renal disease (ESRD), but how chronic kidney disease (CKD) differs in relation to demographics, comorbidities and outcomes has not been studied. We aimed to study differences in SA individuals with CKD compared with White individuals.
Akiko Nagata, Makoto Nasu, Yusuke Kaida, Yosuke Nakayama, Yuka Kurokawa, Nao Nakamura, Ryo Shibata, Takuma Hazama, Takahiro Tsukimura, Tadayasu Togawa, Seiji Saito, Hitoshi Sakuraba, Kei Fukami
doi : 10.1093/ndt/gfaa324
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 115–125
Fabry disease (FD), an X-linked lysosomal storage disorder caused by a deficiency in alfa-galactosidase A (?-Gal A) activity due to mutations in the GLA gene, has a prevalence of 0–1.69% in patients undergoing haemodialysis; however, its prevalence in patients with chronic kidney disease (CKD) Stages 1–5 is unknown.
Rianne W de Jong, Kitty J Jager, Raymond C Vanholder, Cécile Couchoud, Mark Murphy, Axel Rahmel, Ziad A Massy, Vianda S Stel
doi : 10.1093/ndt/gfaa342
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 126–138
Access to forms of dialysis, kidney transplantation (Tx) and comprehensive conservative management (CCM) for patients with end-stage kidney disease (ESKD) varies across European countries. Attitudes of nephrologists, information provision and decision-making may influence this access and nephrologists may experience several barriers when providing treatments for ESKD.
Sahir Kalim, Anders H Berg, Subbian Ananth Karumanchi, Ravi Thadhani, Andrew S Allegretti, Sagar Nigwekar, Sophia Zhao, Anand Srivastava, Dominic Raj, Rajat Deo, Anne Frydrych, Jing Chen, James Sondheimer, Tariq Shafi, Matthew Weir, James P Lash, the CRIC Study Investigators
doi : 10.1093/ndt/gfaa347
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 139–147
Protein carbamylation is a post-translational protein modification caused, in part, by exposure to urea’s dissociation product cyanate. Carbamylation is linked to cardiovascular outcomes and mortality in dialysis-dependent end-stage kidney disease (ESKD), but its effects in earlier pre-dialysis stages of chronic kidney disease (CKD) are not established.
Luke Pickup, Charalampos Loutradis, Jonathan P Law, Julia J Arnold, Indranil Dasgupta, Pantelis Sarafidis, Jonathan N Townend, Paul Cockwell, Charles J Ferro
doi : 10.1093/ndt/gfaa333
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 148–158
Acute kidney injury (AKI) in hospital-admitted patients is a common complication associated with increased mortality. The diagnosis of AKI relies on the ascertainment of peak increase in serum creatinine (SCr). This study evaluated the incidence of AKI using the increase from mean 7–365?days pre-admission (AKIpre) and admission (AKIadm) SCr levels, and examined the associations of AKI and changes in SCr levels with all-cause mortality.
Emily J See, Aminu K Bello, Adeera Levin, Meaghan Lunney, Mohamed A Osman, Feng Ye, Gloria E Ashuntantang, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Sara Davison, Mohammad Ghnaimat, Paul Harden, Htay Htay, Vivekanand Jha, Kamyar Kalantar-Zadeh, Peter G Kerr, Scott Klarenbach, Csaba P Kovesdy, Valerie Luyckx, Brendon Neuen, Donal O’Donoghue, Shahrzad Ossareh, Jeffrey Perl, Harun Ur Rashid, Eric Rondeau, Saad Syed, Laura Sola, Irma Tchokhonelidze, Vladimir Tesar, Kriang Tungsanga, Rumeyza Turan Kazancioglu, Angela Yee-Moon Wang, Chih-Wei Yang, Alexander Zemchenkov, Ming-Hui Zhao, Kitty J Jager, Fergus Caskey, Vlado Perkovic, Kailash K Jindal, Ikechi G Okpechi, Marcello Tonelli, John Feehally, David C Harris, David W Johnson
doi : 10.1093/ndt/gfaa343
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 159–167
Health information systems (HIS) are fundamental tools for the surveillance of health services, estimation of disease burden and prioritization of health resources. Several gaps in the availability of HIS for kidney disease were highlighted by the first iteration of the Global Kidney Health Atlas.
Kathryn B Dansie, Christopher E Davies, Rachael L Morton, Carmel M Hawley, David W Johnson, Jonathan C Craig, Jeremy R Chapman, Bruce A Cooper, Carol A Pollock, David C H Harris, Stephen P McDonald
doi : 10.1093/ndt/gfab270
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 168–174
The impact of research findings on clinical practice usually remains uncertain and unmeasured. To address this problem, we examined the long-term clinical and economic impact of the Initiating Dialysis Early and Late (IDEAL) trial using data from the Australia and New Zealand Dialysis and Transplant Registry.
Maria Pippias, Vianda S Stel, Miha Arnol, Frederike Bemelman, Stefan P Berger, Jadranka Buturovic Buturovic Ponikvar, Reinhard Kramar, Ángela Magaz, Maurizio Nordio, Hessel Peters-Sengers, Anna Varberg Reisæter, Søren S Sørensen, Ziad A Massy, Kitty J Jager
doi : 10.1093/ndt/gfab156
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 175–186
We investigated 10-year trends in deceased donor kidney quality expressed as the kidney donor risk index (KDRI) and subsequent effects on survival outcomes in a European transplant population.
Ian A Strohbehn, Sarah Street, Donald Chute, Harish Seethapathy, Meghan Lee, Rituvanthikaa Seethapathy, Zsofia D Drobni, Osama Rahma, Tomas G Neilan, Leyre Zubiri, Kerry Reynolds, Meghan E Sise
doi : 10.1093/ndt/gfab240
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 187–189
Anusha S Shankar, Sjoerd A A van den Berg, Hector Tejeda Mora, Zhaoyu Du, Hui Lin, Sander S Korevaar, Ronald van der Wal, Thierry P P van den Bosch, Marian C Clahsen-van Groningen, Joost Gribnau, Ewout J Hoorn, Carla C Baan, Martin J Hoogduijn
doi : 10.1093/ndt/gfab264
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 190–193
Rianne W de Jong, Kitty J Jager, Tom H F Broens, Vianda S Stel
doi : 10.1093/ndt/gfab206
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 194–196
Marie Yan, Joseph H Puyat, Hennady P Shulha, Edward G Clark, Adeera Levin, James C Johnston
doi : 10.1093/ndt/gfab222
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Pages 197–198
Rainer Oberbauer, Timothy W Meyer
doi : 10.1093/ndt/gfab256
Nephrology Dialysis Transplantation, Volume 37, Issue 1, January 2022, Page 199
Do you want to add Medilib to your home screen?